266 related articles for article (PubMed ID: 25859034)
1. Drug Development. Are trade secrets delaying biosimilars?
Price WN; Rai AK
Science; 2015 Apr; 348(6231):188-9. PubMed ID: 25859034
[No Abstract] [Full Text] [Related]
2. Biosimilars.
Bagel J
J Drugs Dermatol; 2014 Jul; 13(7):788-90. PubMed ID: 25007360
[No Abstract] [Full Text] [Related]
3. First biosimilar drug approved for sale in the United States.
Hede K
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444
[No Abstract] [Full Text] [Related]
4. Biosimilars battle rages on, Amgen fights both sides.
Senior M
Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
[No Abstract] [Full Text] [Related]
5. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle?
Reinke T
Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515
[TBL] [Abstract][Full Text] [Related]
6. The Biosimilar Pipeline Seams Seem To Be Bursting.
Reinke T
Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet.
Rychlick N
Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768
[TBL] [Abstract][Full Text] [Related]
8. Competition in the Age of Biosimilars.
Chandra A; Vanderpuye-Orgle J
JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179
[No Abstract] [Full Text] [Related]
9. Biotech innovators jump on biosimilars bandwagon.
Moran N
Nat Biotechnol; 2012 Apr; 30(4):297-9. PubMed ID: 22491261
[No Abstract] [Full Text] [Related]
10. Europe offers example for approving biosimilars.
Carroll J
Manag Care; 2013 Sep; 22(9):4-5. PubMed ID: 24167835
[No Abstract] [Full Text] [Related]
11. The comparability conundrum: biosimilars in the United States, Europe and Canada.
Courage N; Parsons A
Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
[TBL] [Abstract][Full Text] [Related]
12. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
Epstein RA
Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
[TBL] [Abstract][Full Text] [Related]
13. Bullying biosimilars: cheaper drugs stymied in USA.
The Lancet Gastroenterology Hepatology
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
[No Abstract] [Full Text] [Related]
14. Obstacles to the Adoption of Biosimilars for Chronic Diseases.
Hakim A; Ross JS
JAMA; 2017 Jun; 317(21):2163-2164. PubMed ID: 28459924
[No Abstract] [Full Text] [Related]
15. Biosimilars: where we were and where we are.
Challand R; Gorham H; Constant J
J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: the need, the challenge, the future: the FDA perspective.
Epstein MS; Ehrenpreis ED; Kulkarni PM;
Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
[TBL] [Abstract][Full Text] [Related]
17. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?
Jordan JB; Christl L
Expert Opin Drug Saf; 2020 Mar; 19(3):229-232. PubMed ID: 32098520
[No Abstract] [Full Text] [Related]
18. Forum discusses biosimilars, better biologicals.
Thompson CA
Am J Health Syst Pharm; 2011 Dec; 68(23):2210. PubMed ID: 22095804
[No Abstract] [Full Text] [Related]
19. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Grabowski HG; Guha R; Salgado M
Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
[TBL] [Abstract][Full Text] [Related]
20. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
